-
EP3889180
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3889180
| EP3889180 - HUMANIZED ANTI-HUMAN OX40 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 03.09.2021 Database last updated on 02.11.2024 | |
| Former | The international publication has been made Status updated on 06.06.2020 | Most recent event Tooltip | 01.12.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Nanjing GenScript Biotech Co., Ltd. 28 Yongxi Road Jiangning Science Park Nanjing, Jiangsu 211100 / CN | [2021/40] | Inventor(s) | 01 /
YIN, Liusong Room 55-203, 88 Shangyuan Street, Jiangning District Nanjing, Jiangsu 211100 / CN | 02 /
ZHOU, Tielin 28 Yongxi Road, Jiangning Science Park Nanjing, Jiangsu 211100 / CN | 03 /
JIANG, Xinpo 2989 Skeena Street Vancouver, British Columbia V5M 4T2 / CA | 04 /
FANG, Zhuo 28 Yongxi Road, Jiangning Science Park Nanjing, Jiangsu 211100 / CN | 05 /
MI, Yanling 28 Yongxi Road, Jiangning Science Park Nanjing, Jiangsu 211100 / CN | 06 /
WU, Chunchen 28 Yongxi Road, Jiangning Science Park Nanjing, Jiangsu 211100 / CN | [2021/40] | Representative(s) | Synergy IP Group AG Leonhardsgraben 52 Postfach 4001 Basel / CH | [N/P] |
| Former [2021/40] | Pharma Patents International AG Leonhardsgraben 52 4051 Basel / CH | Application number, filing date | 19891274.3 | 26.11.2019 | [2021/40] | WO2019CN120808 | Priority number, date | CN201811420381 | 26.11.2018 Original published format: CN201811420381 | [2021/40] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020108463 | Date: | 04.06.2020 | Language: | ZH | [2020/23] | Type: | A1 Application with search report | No.: | EP3889180 | Date: | 06.10.2021 | Language: | EN | [2021/40] | Search report(s) | International search report - published on: | CN | 04.06.2020 | (Supplementary) European search report - dispatched on: | EP | 02.12.2022 | Classification | IPC: | C07K16/28, C12N15/13, A61K39/395, A61P35/00, A61P37/02 | [2021/40] | CPC: |
C07K16/2878 (EP,US);
A61P35/00 (EP);
A61P37/02 (EP);
C07K2317/24 (EP,US);
C07K2317/33 (EP,US);
C07K2317/565 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/40] | Title | German: | HUMANISIERTER MONOKLONALER ANTI-HUMAN-OX40-ANTIKÖRPER, HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON | [2021/40] | English: | HUMANIZED ANTI-HUMAN OX40 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF | [2021/40] | French: | ANTICORPS MONOCLONAL HUMANISÉ ANTI-OX40, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION | [2021/40] | Entry into regional phase | 21.06.2021 | Translation filed | 28.06.2021 | National basic fee paid | 28.06.2021 | Search fee paid | 28.06.2021 | Designation fee(s) paid | 28.06.2021 | Examination fee paid | Examination procedure | 28.06.2021 | Examination requested [2021/40] | 19.06.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 30.11.2021 | Renewal fee patent year 03 | 30.11.2022 | Renewal fee patent year 04 | 30.11.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2015153513 (GENENTECH INC [US], et al) [Y] 1-13 * claim 69; tables 2,3,8,9 *; | [Y]WO2016057667 (MEDIMMUNE LLC [US]) [Y] 1-13 * example all; claims 1,17; table 2 *; | [XY]WO2017021910 (GLAXOSMITHKLINE IP DEV LTD [GB], et al) [X] 1,7-13 * page 140, paragraph 2; figures 1,2; claims 1,2,9,10; sequence 5 * [Y] 1-13; | [YP]CN109232738 (GENSCRIPT NANJING CO LTD) [YP] 1-13 * the whole document *; | [T] - CEBADA JORGE ET AL, "OX40 agonists for cancer treatment: a patent review", EXPERT OPINION ON THERAPEUTIC PATENTS, GB, vol. 31, no. 1, doi:10.1080/13543776.2021.1825688, ISSN 1354-3776, (20201006), pages 81 - 90, URL: http://dx.doi.org/10.1080/13543776.2021.1825688, XP093001557 [T] * page 84 - page 85; table 1 * DOI: http://dx.doi.org/10.1080/13543776.2021.1825688 |